Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next three days.
In the meantime, you can enjoy access to all the latest news, events and resources for different therapy areas on our website.
Sunday 5th September
19:15-20:45 KSA
COPD: Same problem, different recommendations across guidelines – What do I do?
Chaired by Professor Neil Barnes
Global Clinical Science Lead, GSK
GSK COPD Symposia at ERS 2021 5th–8th September
Welcome to the GSK COPD Symposia webpage – your one-stop resource for all information on the GSK symposia sessions, expert speakers and presentations.
About the COPD Symposia
About the COPD Symposia
GSK is hosting two virtual COPD Symposia at the European Respiratory Society International Congress this year. We will discuss COPD guidelines, focusing on the areas where the recommendations may differ, and about the current challenges of managing COPD, such as remote patient care during the COVID-19 pandemic.
Hear from the session chairs
COPD: Same problem, different recommendations across guidelines – What do I do?
Video player requires JavaScript enabled. You can download this video here: https://videos.gskstatic.com/pharma/GSKpro/SaudiArabia/MP4/ers_2021_1_minute_chair_video_sympo_copd_recommendations_pr_neil_saudi.mp4
Chaired by Professor Neil Barnes
Global Clinical Science Lead, GSK
What are the challenges and solutions for managing patients with COPD in 2021?
Video player requires JavaScript enabled. You can download this video here: https://videos.gskstatic.com/pharma/GSKpro/SaudiArabia/MP4/ers_2021_chair_video_sympo_copd_management_pr_meilan_saudi.mp4
Chaired by Professor MeiLan Han
Professor of Internal Medicine, University of Michigan, USA
Agenda
We are excited to announce our expert panel of speakers, who will share their insights and knowledge on COPD management. To plan your attendance, please see the schedule below.
Who should start with dual versus mono bronchodilator therapy?
Professor Claus F. Vogelmeier
Philipps-University of Marburg, Germany
Which patients should receive ICS-containing therapy?
Dr Jean Bourbeau
McGill University, Canada
What is the rationale to stop or continue ICS-containing therapy?
Professor Dave Singh
University of Manchester, UK
COPD in the frail patient: Factors affecting inhaler performance
Raj Sharma, PhD
Global Medical Affairs Lead, GSK
Tuesday 7th September
21:00-22:30 KSA
What are the challenges and solutions for managing patients with COPD in 2021?
Chaired by Professor MeiLan Han
Professor of Internal Medicine, University of Michigan, USA
COVID learnings: Remote assessment
Professor Janwillem Kocks
University Medical Center Groningen,
The Netherlands
Eosinophils in clinical practice
Professor MeiLan Han
Professor of Internal Medicine, University of Michigan, USA
COPD and bronchiectasis
Professor James Chalmers
University of Dundee, UK
Vaccination
Professor Tobias Welte
Hannover University School of Medicine, Germany
Meet our experts
Chairs
-
Neil Barnes Introduction
Neil Barnes is a Global Clinical Science Lead in the Global Respiratory Therapy Area at GSK, and was Respiratory Franchise Medical Head from 2013 to 2019. Until October 2013 he was a consultant respiratory physician at the London Chest Hospital, Barts Health NHS Trust and Professor of Respiratory Medicine at Barts and the London School of Medicine and Dentistry, London, UK. His research focuses on the mechanisms and pharmacology of asthma and COPD, and clinical trial design and interpretation. Professor Barnes has served as an associate editor for Thorax, has been a reviewer for a wide range of general and respiratory journals, and has published over 250 peer-reviewed papers, book chapters, editorials and reviews.
-
MeiLan Han Introduction
MeiLan Han is Professor of Internal Medicine in the Division of Pulmonary and Critical Care Medicine at the University of Michigan Health System, and Director of the Michigan Airways Program. Her research focuses on defining disease phenotypes in COPD, with a goal of advancing the development of personalised medicine. Professor Han is an associate editor for the American Journal of Respiratory and Critical Care Medicine, serves on the Editorial Board for several other journals and is a Scientific Advisory Committee member for the COPD Foundation and the American Lung Association.
Speakers
-
Claus F. Vogelmeier Introduction
Claus F. Vogelmeier is Professor of Medicine and Head of the Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg at the Philipps-University of Marburg, Germany. He is a member of the Board of Directors of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) and serves as the chair of the GOLD Science Committee. He is also an Honorary Fellow of both the ERS and the American Thoracic Society.
-
Jean Bourbeau Introduction
Jean Bourbeau is a pulmonologist and professor in the Department of Medicine and Epidemiology and Biostatistics of the Faculty of Medicine, McGill University. He is the director of the Research Institute of the McGill University Health Centre (MUHC) for the Center of Innovative Medicine, as well as the COPD Clinic and the Pulmonary Rehabilitation Unit at the MUHC Montreal Chest Institute. His research focuses on COPD and the integration of disease with self-management and pulmonary rehabilitation programmes for health care professionals and patients (www.livingwellwithcopd.com). Dr Bourbeau currently sits on the GOLD Science Committee and has had an international impact in the field of research, clinical practice and in the public domain.
-
Dave Singh Introduction
Dave Singh is Professor of Clinical Pharmacology & Respiratory Medicine at the University of Manchester. He graduated in medicine from Cambridge University and then specialised in clinical pharmacology and respiratory medicine. His research interest is the development of new drugs for asthma and COPD. He is the Medical Director of the Medicines Evaluation Unit, where he has acted as principal investigator in over 400 clinical trials. He is a member of the GOLD Science Committee, Chair of the ERS airway pharmacology group, and an editor of the European Respiratory Journal and European Respiratory Review. He is a Fellow of the ERS and of the British Pharmacology Society. He has over 350 publications.
-
Raj Sharma Introduction
Raj Sharma is a Global Medical Affairs Lead in the Respiratory Therapy area at GSK based in Brentford, London in the UK. He has had a number of roles in Clinical Development and Medical Affairs and has led cross-functional teams relating to GSK's inhaler technologies including MDIs, DPI development and connected inhaler systems. He has also led a number of GSK's external collaborations in device development. Raj obtained his PhD in Respiratory Pharmacology at Imperial College London where he conducted research in autonomic receptor dysfunction in airway diseases.
-
Janwillem Kocks Introduction
Janwillem Kocks is a practising general practitioner and Professor of Inhalation Medicine at the Observational and Pragmatic Research Institute in Singapore and Managing Director of the General Practitioners Research Institute. He is President of the International Primary Care Respiratory Group (IPCRG). His current research focuses on diagnosis and individualised management of both asthma and COPD in primary care including improving inhalation technique by education and smart inhalers.
-
James Chalmers Introduction
James Chalmers is the British Lung Foundation Chair of Respiratory Research at the University of Dundee and an honorary consultant physician at Ninewells Hospital. His clinical and research interests are in respiratory infections including pneumonia, COVID-19, bronchiectasis and COPD. He has chaired a number of international guidelines including the current ERS COVID-19 task force. He is currently Deputy Chief Editor of the European Respiratory Journal.
-
Tobias Welte Introduction
Tobias Welte is Professor of Pulmonary Medicine and Head of the Department of Pulmonary and Infectious Diseases at Hannover University School of Medicine. In addition to his work as a pulmonologist, his research focuses on intensive care and infection medicine, and he is a proven expert in the field of influenza research. In 2019, he was awarded the prestigious Balzan Award for Medicine for his lifetime achievement in infectious disease and intensive care medicine. Professor Welte is a member of the board of the German Center for Lung Research (DZL) and is the Director of the Biomedical Research in Endstage and Obstructive Lung Disease (BREATH) DZL site in Hanover.
ERS 2021 – the largest respiratory meeting in the world
The ERS International Congress is a once-a-year occasion when the world’s respiratory experts meet to present and discuss the latest scientific and clinical advances across the entire field of respiratory medicine.
Taking place from 5th to 8th September, ERS 2021 will be a dynamic digital experience with an outstanding scientific programme.
*This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by a third party.
PM-SA-CPU-WCNT-210001 Date of preparation: July 2021
